Dr. Oz: Fraud Findings Could Double Medicare Trust Fund Life
What this video covers
Bloomberg Television interviews CMS Administrator Dr. Mehmet Oz on the sidelines of a Republican convention event — a noisy hall, with Oz due on stage that night. In just over eight minutes he covers the most-favored-nation drug-pricing deals, the $50 Medicare GLP-1 program, why states are slower to adopt GLP-1 coverage in Medicaid, healthcare fraud and the Medicare trust fund, and his prescription of prevention over surgery.
Key points
- Oz credits most-favored-nation deals with the top 26 pharmaceutical companies — covering 90% of branded drugs sold in drugstores — for what he calls the largest drop in consumer pharmaceutical prices in 63 years, and says Congress should codify the deals because the contracts expire at the end of the administration.
- Oz says Medicare offers GLP-1 medications to eligible beneficiaries at $50 a month instead of the roughly $1,200 they used to cost, while Medicaid adoption lags because governors fear the upfront cost; his pitch to governors is that reducing obesity complications saves taxpayers money within two years, since those complications drive about two-thirds of healthcare spending.
- Oz estimates about $100 billion in healthcare fraud overall and says the Treasury Department identified more than $20 billion in suspected money laundering and fraud; recovering it, he says, would double the Medicare trust fund’s remaining life — from insolvency in about six years to 12 or 13 years.
- Oz says the share of Americans who can easily access their own medical records jumped from 5% last year to 60% this year, and argues that two-thirds of the roughly $2 trillion Medicare and Medicaid spend goes to chronic disease: “We’re twice as expensive per capita as other countries because we’re twice as fat.”
- On drug-deal transparency, Oz points viewers to TrumpRx.gov for the negotiated prices and says a rule making hospital prices easier to access is coming within the month; Secretary Kennedy has said the deal details would be made public.
- Asked how clinical AI should be paid for — a question he struggles to hear over the hall noise — Oz pivots to prevention, saying much of his own heart-surgery work could have been avoided by proactive steps weeks or months earlier, and that the affordability battle is won “in our kitchens, our living rooms, our bedrooms,” not the operating room.